Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05931835
Other study ID # P001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 15, 2024
Est. completion date October 30, 2024

Study information

Verified date May 2024
Source LUMA Vision Ltd.
Contact Elke Sommerijns, MSc
Phone +32479767156
Email elke.sommerijns@lumavision.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of the study is to evaluate the performance of the VERAFEYE System in subjects entitled to undergo a standard of care ablation or closure procedure. Results from this study will be used to guide development and refinement the VERAFEYE System. The study is not designed to collect data for product approval and as such does not have a safety or efficacy endpoint.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 20
Est. completion date October 30, 2024
Est. primary completion date October 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Key Inclusion Criteria: - Subject is 18 to 80 years of age at the time of consent - Subject is scheduled to undergo a standard of care, de-novo catheter-ablation procedure to treat typical AFL or AF; or left atrial appendage (LAA)/ atrial septal defect (ASD) closure procedure - Subject is able to understand and willing to provide written informed consent Key Exclusion Criteria: - Any of the following within 6 months prior to enrolment: - Cardiac surgery including coronary artery bypass grafting, ventriculotomy, atriotomy - Thromboembolic event (stroke), transient ischemic attack (TIA) or neurological disturbances - Myocardial infarction - Any surgical or percutaneous cardiac procedure including coronary intervention and cardiac ablation - Dilated or hypertropic cardiomyopathy - Any planned surgical or endovascular intervention within 30 days before or after the ablation, or LAA/ASD closure procedure. - Any of the following cardiac conditions: - New York Heart Association (NYHA) class IV - Left ventricular ejection fraction (LVEF) < 30% - Implanted with a cardiac rhythm management device (pacemaker, CRT, ICD, loop recorder) - Presence of intramural thrombus, tumor, or other abnormality that precludes vascular access, catheter introduction, or manipulation - Active coronary ischemia, significant valvular heart disease, or hemodynamically significant congenital cardiac abnormality - Body mass index (BMI) > 40 kg/m2 - Body weight < 50kg - Pregnant women or women who plan to become pregnant during the course of their participation in the study (women should either be of non- childbearing potential at the time of enrolment (as documented in the medical file) or have a negative pregnancy test within the previous 7 days prior to the ablation, or LAA/ASD closure procedure) - Life expectancy less than 12 months - Subjects who are currently enrolled in another study - Subjects with a thrombus or pericardial effusion detected in the LA/LAA during standard of care imaging

Study Design


Intervention

Device:
VERAFEYE System
The VERAFEYE System will be used during standard of care, catheter-based treatments for atrial flutter or atrial fibrillation; or left atrial appendage/atrial septal defect closure procedures.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
LUMA Vision Ltd.

Outcome

Type Measure Description Time frame Safety issue
Primary Physician Feedback on VERAFEYE System The objective of the study is to collect physician feedback by means of a questionnaire on the VERAFEYE System. Results from this study may be used to guide development and refinement of the VERAFEYE System. During the procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Completed NCT04571385 - A Study Evaluating the Efficacy and Safety of AP30663 for Cardioversion in Participants With Atrial Fibrillation (AF) Phase 2
Terminated NCT04115735 - His Bundle Recording From Subclavian Vein
Completed NCT05366803 - Women's Health Initiative Silent Atrial Fibrillation Recording Study N/A
Completed NCT02864758 - Benefit-Risk Of Arterial THrombotic prEvention With Rivaroxaban for Atrial Fibrillation in France
Recruiting NCT05442203 - Electrocardiogram-based Artificial Intelligence-assisted Detection of Heart Disease N/A
Completed NCT05599308 - Evaluation of Blood Pressure Monitor With AFib Screening Feature N/A
Completed NCT03790917 - Assessment of Adherence to New Oral anTicoagulants in Atrial Fibrillation patiEnts Within the Outpatient registrY
Enrolling by invitation NCT05890274 - Atrial Fibrillation (AF) and Electrocardiogram (EKG) Interpretation Project ECHO N/A
Recruiting NCT05266144 - Atrial Fibrillation Patients Treated With Catheter Ablation
Recruiting NCT05316870 - Construction and Effect Evaluation of Anticoagulation Management Model in Atrial Fibrillation N/A
Not yet recruiting NCT06023784 - The Impact of LBBAP vs RVP on the Incidence of New-onset Atrial Fibrillation in Patients With Atrioventricular Block N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Recruiting NCT04092985 - Smart Watch iECG for the Detection of Cardiac Arrhythmias
Completed NCT04087122 - Evaluate the Efficiency Impact of Conducting Active Temperature Management During Cardiac Cryoablation Procedures N/A
Completed NCT06283654 - Relieving the Emergency Department by Using a 1-lead ECG Device for Atrial Fibrillation Patients After Pulmonary Vein Isolation
Recruiting NCT05416086 - iCLAS™ Cryoablation System Post-Market Clinical Follow-up (PMCF) Study N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)
Completed NCT04546763 - Study Watch AF Detection At Home
Completed NCT03761394 - Pulsewatch: Smartwatch Monitoring for Atrial Fibrillation After Stroke N/A